Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 16Active not recruiting 6Not yet recruiting 1Enrolling by invitation 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Breast Neoplasms 54Neoplasms 47Colorectal Neoplasms 31Prostatic Neoplasms 27Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 21Leukemia, Myeloid, Acute 19Recurrence 12Stomach Neoplasms 11Multiple Myeloma 11Melanoma 11Head and Neck Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Ovarian Neoplasms 9Uterine Cervical Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Pancreatic Neoplasms 8Neoplasm Metastasis 8Myelodysplastic Syndromes 8Lymphoma, Non-Hodgkin 8Lymphoma 8Glioma 8Brain Neoplasms 8Motor Activity 7Esophageal Neoplasms 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Leukemia 6Hodgkin Disease 6Colonic Neoplasms 6

Interventions

pembrolizumab 1PT-100 dipeptide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neuroendocrine Tumors × 30 days × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡